摘要视网膜母细胞瘤(RB)的全身化学药物治疗(化疗)对顽固性或复发性RB玻璃体腔种植者治疗效果较差.近年来,通过玻璃体腔化疗(IVitC)治疗进展期RB及RB玻璃体腔种植患者已取得较好疗效,有望成为治疗进展期RB及RB玻璃体腔种植的一种重要方法.然而,考虑到眼外转移的风险,对RB患者行IVitC仍有较多争议,且对于国际分期E期的患眼仍无法替代眼球摘除.如何慎重选择适应证以及合适的药物种类和浓度,如何进行治疗技术的优化以减轻可能发生的毒副作用,以及长期疗效和可能的毒副作用尚需密切随访及进一步研究.

abstractsNowadays,one of the most challenging aspects of retinoblastoma (RB) therapy is how to control the resistant or recurrent viable vitreous seeds,for which intravenous chemotherapy appears to be ineffective.Recently,intravitreal chemotherapy offers another option to control advanced stage and vitreous seeds of RB,and may be a promising new approach to RB therapy.However,intravitreal injection for RB patients raises considerable controversy due to concerns of possible extraocular extension along the injection route,and should not replace the primary standard of care for bilateral RB or group E eyes of RB.Close follow-up and further studies are needed to determine appropriate indications,to determine the effective drugs and concentrations,to optimize RB therapy protocols and to investigate the relationship between long-term efficacy and toxicities.